The Evolution of Adjuvant Therapy for Melanoma
- 139 Downloads
Purpose of Review
The past decade has been a time of remarkable advancement in the field of adjuvant therapy for patients with resected high-risk melanoma. Here, we review the data for adjuvant melanoma and raise questions about the best choice of therapy for an individual patient.
There have been several new adjuvant approvals including immunotherapy and targeted therapy approaches. Nivolumab is approved for patients with nodal involvement or metastatic disease after resection. Pembrolizumab is approved for patients with nodal involvement after resection. In addition, the combination of dabrafenib and trametinib is approved in patients’ nodal involvement after resection whose tumors harbor BRAFV600E/K mutations.
New therapeutic opportunities have provided promising options for patients with high-risk disease. These advances have significantly challenged the previous standard-of-care for this population of patients. Data is still forthcoming regarding durability of benefit and safety of these new treatments.
KeywordsMelanoma Adjuvant Immunotherapy BRAF
Compliance with Ethical Standards
Conflict of Interest
Justine V. Cohen has received compensation from Sanofi-Genzyme and Bristol-Myers Squibb for service as a consultant. Elizabeth I. Buchbinder has received compensation from Bristol-Myers Squibb, Trieza Therapeutics, and Novartis for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14:7–17.CrossRefGoogle Scholar
- 5.Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013:CD008955.Google Scholar
- 10.Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30:3810–8.PubMedCrossRefGoogle Scholar
- 12.Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666–73.PubMedCrossRefPubMedCentralGoogle Scholar
- 16.• Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019;119:1–10 Long-term follow-up results from the phase III EORTC 18071 trial of adjuvant ipilimumab 10 mg/kg versus placebo. This 5-year follow-up showed sustained improvement in RFS, distant metastasis free survival and OS. PubMedCrossRefPubMedCentralGoogle Scholar
- 17.Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18:393–403.PubMedPubMedCentralCrossRefGoogle Scholar
- 18.Tarhini AA, Lee SJ, Hodi FS, et al. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol. 2017;35:9500.CrossRefGoogle Scholar
- 21.•• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35 This phase III trial (CheckMate 238) randomized patients with resected melanoma to adjuvant nivolumab vs ipilimumab. Patients who received nivolumab had improved RFS and fewer immune-related adverse effects. PubMedCrossRefPubMedCentralGoogle Scholar
- 24.•• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801 This phase III trial (EORTC 1325; Keynote 054) randomized patients with resected melanoma to adjuvant pembrolizumab vs placebo. Patients who received pembrolizumab had prolonged RFS. PubMedCrossRefPubMedCentralGoogle Scholar
- 25.Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, et al. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19:510–20.PubMedCrossRefPubMedCentralGoogle Scholar
- 26.•• Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23 This phase III trial (COMBI-AD) randomized patients with resected BRAF V600E/K mutated melanoma to dabrafenib and trametinib vs two matched placebos. Patients who received the targeted therapy combination had an improved RFS and distant metastases-free survival. PubMedCrossRefPubMedCentralGoogle Scholar
- 27.Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018:JCO1801219.Google Scholar
- 30.Gerbasi ME, Stellato D, Ghate SR, et al. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective. J Med Econ. 2019:1–10.Google Scholar
- 35.• Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22 The MSLT2 trial presented data showing completion lymph node dissections improves local control and guides prognostication however does not increase survival in patients with sentinel lymph node metastases from melanoma. PubMedPubMedCentralCrossRefGoogle Scholar
- 47.Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36:667–73.CrossRefGoogle Scholar